Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of eRapa™ for the treatment of Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $3 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), reported a 75% non-progression rate at 12 months and a median decrease in overall polyp burden of 17%. Notably, Cohort 2 showed an 81% non-progression rate and a 29% median decrease in polyp burden. These results were presented by Dr. Carol Burke at the 2024 InSIGHT bi-annual meeting in Barcelona. The Phase 3 study of eRapa in FAP will be supported by a $17 million CPRIT grant. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability...Show More